Dmitry Samarsky

Biography

Dr Samarsky brings outstanding and highly relevant expertise in RNA therapeutics with a strong track record in the discovery and development of RNA therapeutics. During his career he has authored numerous articles in high impact scientific journals, book chapters and patents and presented, chaired and advised on the subject at more than 100 international scientific conferences. Widely recognised as an expert in the oligonucleotide field, he joined Silence from OliX Pharmaceuticals where he held the position of Senior VP of Technology and Global Business Development. Previously, as Senior VP of Technology and International Business Development at RiboBio, Dmitry played a pivotal role in placing the company amongst the international players in the oligonucleotide field between 2011 and 2015. Prior to that, Dmitry served as Vice President of Technology Development of RXi Pharmaceuticals from 2007 to 2011, co-inventing and developing the company’s key self-delivering RNAi technology. He was previously Director of Technology Development at Dharmacon, while leading an RNAi application laboratory and field application scientists. His career includes postdoctoral work as H. Arthur Smith Fellow for Cancer Research at the University of Massachusetts Medical School, a PhD in Biochemistry and Molecular Biology from the University of Massachusetts Amherst, graduate research at the Institute of Molecular Genetics, Russian Academy of Sciences and a BSc in Biochemistry from the National University of Lviv, Ukraine.

Research Interest

Biology of small non-coding RNAs, gene expression and regulation, RNA interference and antisense technologies, drug development.